The Covid-19 pandemic has seriously depleted the UK’s Brexit drug stockpiles. LLamasoft’s Matthew...
- LLamasoft Q&A: drug stockpiles and the need for advanced scenario planning
- How will COVID-19 impact specialty logistics now and in the future?
- Generics and the Covid-19 pandemic: Q&A with Accord’s Dr Anthony Grosso
- Life-saving logistics in the COVID-19 era
- Q&A: is pharma ready to address the health effects of climate change?
LLamasoft Q&A: drug stockpiles and the need for advanced scenario planning
The Covid-19 pandemic has seriously depleted the UK’s Brexit drug stockpiles. LLamasoft’s Matthew Woodcock explains how contingency planning and the building of resilience can prevent such significant disruption to supply chains and stockpiles in the future.
Generics and the Covid-19 pandemic: Q&A with Accord’s Dr Anthony Grosso
Like all industries, the pharma industry has been disrupted by the Covid-19 pandemic. The generics industry has been impacted particularly by supply chain problems and huge surges in demand for existing medicines. Accord’s head of scientific affairs Dr Anthony Grosso explains how the industry has worked to overcome these challenges and respond to the needs of patients, as well as become more prepared for future healthcare emergencies.
Q&A: is pharma ready to address the health effects of climate change?
As climate change makes its presence felt, is pharma ready to play a leading role in addressing the global health threats that global warming presents? With the anticipated growth of vector-borne diseases, respiratory disease, bacterial diarrhoea and malnutrition, how can pharma R&D and the supply chain be reformed to help tackle the threat? Abi Millar finds out.
Covid-19 pandemic: knock-on effects for pharma supply chains
Covid-19 originated in China, which is where the clear majority of APIs for drugs are manufactured; China’s lockdown had a knock-on effect on its neighbour India, which relies on those APIs to produce generic drugs. What long-term impact could this have on supply chains and could it push pharma companies to seek to move their API manufacturing back to home soil?
Akron Biotechnology’s Ancillary Materials Manufacturing Facility, Sarasota, Florida
Akron Biotechnology is developing a manufacturing facility in the city of Sarasota in Florida, US to produce cell and gene therapy materials and technologies.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.